Sanofi wins U.S. approval to sell dengue vaccine but with major restrictions

22:07 EDT 1 May 2019 | Reuters

The U.S. Food and Drug Administration on Wednesday gave Sanofi SA's dengue vaccine Dengvaxia a very narrow approval as the company continues to suffer from evidence that its vaccine, which took 20 years to develop, can cause severe infections in some...

More From BioPortfolio on "Sanofi wins U.S. approval to sell dengue vaccine but with major restrictions"